Interestingly, cancer cell-specific genetic knockout of PARP1 in non-small cell lung cancer mouse models induces T lymphocyte-mediated tumor growth control coupled with signs of T cell activation in the local tumor microenvironment, suggesting that therapeutic PARP1 inhibitors might modulate the tumor microenvironment [48]. Here, PARP1 is linked to non-small cell lung carcinoma.